Inspired by professional experiences gathered in the field of sensor development, co-founders Tej Patel and Ryan Revilla asked the question: Why is there not a better diagnostic system on the market that can conduct a variety of tests at the location of the patient?
Founded in 2013
Co-founders Tej Patel and Ryan Revilla thought they could improve medical outcomes by building an inexpensive, point-of-care analyzer using Printed Circuit-Board (PCB) manufacturing technology. They began to develop the very first Fluxergy prototype out of Ryans apartment in San Diego, California. It was called it the FluxDx1.
Backed by leading tech investor
The showcase of the FluxDx1 device is what attracted the attention of Kingston Technology co-founder, John Tu.
He was impressed with the unique use of PCB manufacturing techniques used to create Fluxergy Cards and decided to make an investment into the company.
A novel way to test for HIV-1
Over 9 million people do not know they have HIV, globally. Additionally, millions do not have reliable access to tests that determine if anti-retroviral therapy is working effectively.
In 2015, Fluxergy started development on a novel point-of-care HIV-1 PCR assay with the goal of it bringing to resource-limited settings around the world.
Infinite testing potential
The Fluxergy Analyzer delivers unlimited testing potential at the point-of-care.
In 2017, we began working on adopting our technology for uses outside of medical industry. Applications include veterinary, food safety, and environmental diagnostics.
An entire lab in one device
After successfully testing our system with various collaborators, we are gearing up to launch our system to our Beta Program partners in veterinary health.*
Lets make diagnostics accessible everywhere.
*The Fluxergy Analyzer is for Research use only (RUO) and is not for use in diagnostic procedures. The Fluxergy Analyzer is not yet cleared by the FDA or USDA for in vitro diagnostic use. None of the statements made on this website have been endorsed by the FDA or USDA.